What is venous thromboembolism (VTE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is VTE?

Venous thromboembolism (VTE) is a collective term that encompasses two related conditions: deep vein thrombosis (DVT), which is a blood clot that forms in the deep veins (typically in the legs), and pulmonary embolism (PE), which occurs when a clot breaks off and travels to the lungs. 1, 2

Clinical Significance

VTE represents a major cause of cardiovascular morbidity and mortality:

  • Third leading cause of cardiovascular death worldwide, after myocardial infarction and stroke 3
  • Accounts for 5-10% of all in-hospital deaths directly from PE 1
  • Incidence of approximately 1 case per 1,000 persons per year in the United States 1
  • Results in 200,000-300,000 hospitalizations annually 1

Pathophysiology

VTE develops through a combination of:

  • Blood stasis
  • Plasma hypercoagulability
  • Endothelial dysfunction

The process typically starts in the valve pockets of large veins and involves leukocytes, platelets, tissue factor-positive microvesicles, and various coagulation factors 3.

Clinical Consequences

Acute Complications

  • 26% of patients with undiagnosed/untreated PE will have a subsequent fatal embolic event 1
  • Another 26% will experience nonfatal recurrent embolic events 1
  • Immediate risks include chest pain, shortness of breath, and death 4

Long-term Complications

  • Postthrombotic syndrome - causes lifelong limb pain and edema 2, 4
  • Post-PE syndrome and chronic thromboembolic pulmonary hypertension 5
  • Recurrence rate of approximately 20% after 5 years 2
  • Significant adverse impact on quality of life 5

Risk Factors

Both genetic and acquired factors contribute to VTE risk 3:

  • Non-O blood groups
  • Factor V Leiden mutation
  • Oral contraceptive use and hormone replacement therapy
  • Advanced age
  • Surgery and hospitalization
  • Long-haul travel
  • Cancer

Most hospitalized medical patients have at least one risk factor for VTE, and this risk persists for several weeks after discharge 1.

References

Research

Venous thrombosis.

Nature reviews. Disease primers, 2015

Research

Update on the management of venous thromboembolism.

Cleveland Clinic journal of medicine, 2017

Research

Basics of diagnosis and treatment of venous thromboembolism.

Journal of thrombosis and haemostasis : JTH, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.